Trial Design
This is a prospective, randomized, double-blind, controlled, and noninferiority trial implemented in First Affiliated Hospital, University of Science and Technology of China (USTC) (Approval No. of the ethics committee: 20171219), and the trial was registered in the Chinese Clinical Trial Registry (ChiCTR2100053517). The trial compliance with ethics guidelines. From November 2021 to March 2022, 88 patients were recruited. Patients were given a detailed explanation of the study protocol and informed of the potential benefits and side effects of the technology’s development. Informed consent was obtained from the patient or family. Figure 1 shows the flow diagram of participant recruitment.